Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06885710 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 20 to 19
    • Start date: Jan 1, 2025 to Dec 31, 2024
    • Eligibility criteria expanded, about 2 words
    v3
  2. Eligibility criteria shortened, about 6 words
    • Study title shortened, about 1 word
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Changhai Hospital
121 trials monitored
See 1 trial at risk
This is a open-label study to evaluate the safety and efficacy of autologous T-cells transfected with messenger ribonucleic acid (mRNA) encoding Hepatitis-B virus (HBV) antigen specific T cell receptor (TCR) in combination with nucleos(t)ide analogues (NAs) in HBeAg-positive and negative chronic hepatitis B patients.
Trial Details
NCT Number NCT06885710
Lead Sponsor Changhai Hospital
Collaborators: Guangzhou Lion TCR Co Ltd
Conditions
(from sponsor)		 Chronic Hepatitis b
Related terms Hepatitis B, Chronic
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov